Achieving Canadian Treat-to-Target Criteria in Moderate-to-Severe Atopic Dermatitis: A Retrospective Analysis of Outcomes from Real-World Canadian Practice - Takeaways - MDSpire

Achieving Canadian Treat-to-Target Criteria in Moderate-to-Severe Atopic Dermatitis: A Retrospective Analysis of Outcomes from Real-World Canadian Practice

  • By

  • Jensen Yeung

  • Parbeer Grewal

  • Mark Legault

  • Jason Stacey

  • Irina Turchin

  • June 20, 2026

  • 0 min

Share

  • 1

    The study evaluated the applicability of Canadian treat-to-target recommendations for moderate-to-severe atopic dermatitis in real-world practice.

  • 2

    Data from 297 patients treated with advanced systemic therapies were analyzed to assess the alignment between treatment targets and clinical decisions.

  • 3

    Achieving or missing treatment targets generally corresponded with decisions to continue or modify treatment among the studied patients.

  • 4

    The study involved 29 dermatologists across Canada, with a diverse range of clinical experience in managing moderate-to-severe atopic dermatitis.

  • 5

    Most patients had a history of previous topical and systemic treatments, with common comorbidities including asthma and allergic rhinitis.

Original Source(s)

Achieving Canadian Treat-to-Target Criteria in Moderate-to-Severe Atopic Dermatitis: A Retrospective Analysis of Outcomes from Real-World Canadian Practice

  • by Jensen Yeung, Parbeer Grewal, Mark Legault, Jason Stacey, Irina Turchin

  • June 20, 2026

Related Content

Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)

Enhancing skin lesion classification using a Tri-Path Attention Stacked Ensemble architecture with Cohen’s Kappa Proportioned Averaging

FDA Approves Less Frequent Lebrikizumab Dosing

Approval adds an every-8-week maintenance option for eligible patients with moderate-to-severe atopic dermatitis.